Corxel US and Amanat Acquisition Corp Announce Definitive Business Combination Agreement to Create Publicly Listed Obesity-Focused Biopharmaceutical Company

Amanat Acquisition Corp (Nasdaq: AMAN) signed a definitive business combination agreement with Corxel US, a clinical-stage obesity biopharmaceutical company, to take it public on Nasdaq under a new name and ticker. The deal includes an oversubscribed ~$300M PIPE from investors including RTW, NEA, and RA Capital, plus Amanat's ~$75M trust, for ~$377M in gross proceeds expected to fund operations through 2029. The combined company will advance CX11, a once-daily oral GLP-1 receptor agonist that achieved up to 11.5% mean body-weight reduction at Week 36 in a U.S. Phase 2 obesity trial, into global Phase 3 development following FDA alignment on trial design.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.